Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy.
Chemotherapy
Combinational immunotherapy
Glutathione response
Intracellular aggregation
Nanoassembly
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
05
03
2020
revised:
15
04
2020
accepted:
05
06
2020
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
The intracellular retention of nanotherapeutics is essential for their therapeutic activity. The immobilization of nanotherapeutics inside target cell types can regulate various cell behaviors. However, strategies for the intracellular immobilization of nanoparticles are limited. Herein, a cisplatin prodrug was synthesized and utilized as a glutathione (GSH)-activated linker to induce aggregation of the cisplatin prodrug/IR820/docetaxel nanoassembly. The nanoassembly has been reprogrammed with peptide-containing moieties for tumor-targeting and PD-1/PD-L1 blockade. The aggregation of the nanoassemblies is dependent on GSH concentration. Evaluations
Identifiants
pubmed: 33996418
doi: 10.1016/j.apsb.2020.06.013
pii: S2211-3835(20)30623-7
pmc: PMC8105769
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1069-1082Informations de copyright
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Références
ACS Nano. 2019 Nov 26;13(11):13445-13455
pubmed: 31670945
Nat Rev Cancer. 2019 Oct;19(10):587-602
pubmed: 31492927
Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52
pubmed: 15386533
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
ACS Appl Mater Interfaces. 2017 Dec 27;9(51):44410-44422
pubmed: 29210279
Sci Adv. 2019 Sep 06;5(9):eaax0937
pubmed: 31523712
Acta Pharm Sin B. 2019 Sep;9(5):1008-1020
pubmed: 31649850
Adv Sci (Weinh). 2018 Feb 26;5(5):1700891
pubmed: 29876215
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
pubmed: 22301798
Nat Mater. 2018 Apr;17(4):361-368
pubmed: 29403054
Adv Mater. 2012 Oct 23;24(40):5476-80
pubmed: 22886872
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
pubmed: 21690347
J Biomed Nanotechnol. 2018 Jun 1;14(6):1107-1116
pubmed: 29843875
Angew Chem Int Ed Engl. 2018 Feb 12;57(7):1813-1816
pubmed: 29276818
Acta Pharm Sin B. 2019 Mar;9(2):410-420
pubmed: 30976492
Adv Drug Deliv Rev. 2014 Feb;66:2-25
pubmed: 24270007
J Biomed Nanotechnol. 2019 Feb 1;15(2):373-381
pubmed: 30596559
Nat Biomed Eng. 2017 Aug;1(8):667-679
pubmed: 31015598
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Nat Mater. 2019 Dec;18(12):1376-1383
pubmed: 31636420
Biomaterials. 2015 Jan;37:425-35
pubmed: 25453970
Sci Adv. 2019 Nov 13;5(11):eaax9250
pubmed: 31763454
ACS Nano. 2018 Mar 27;12(3):2426-2439
pubmed: 29533606
J Control Release. 2019 Aug 28;308:29-43
pubmed: 31252039
ACS Appl Mater Interfaces. 2018 Jan 10;10(1):150-164
pubmed: 29251910
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Nat Rev Mater. 2017;2:
pubmed: 29075517
Acta Pharm Sin B. 2019 Mar;9(2):421-432
pubmed: 30972286
Nat Commun. 2019 Sep 27;10(1):4418
pubmed: 31562357
Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9700-4
pubmed: 26118539
Adv Drug Deliv Rev. 2019 Mar 15;143:37-67
pubmed: 31276708
Nat Nanotechnol. 2015 Apr;10(4):325-32
pubmed: 25822929
Nature. 2015 Oct 1;526(7571):118-21
pubmed: 26374997
Nat Commun. 2019 Oct 24;10(1):4861
pubmed: 31649241
Adv Mater. 2020 Apr;32(13):e1902604
pubmed: 31353770
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415